The Library
Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency
Tools
Butler, Javed, Khan, Muhammad Shahzeb, Friede, Tim, Jankowska, Ewa A., Fabien, Vincent, Goehring, Udo‐Michael, Dorigotti, Fabio, Metra, Marco, Piña, Ileana L., Coats, Andrew J. S., Rosano, Giuseppe, Comin‐Colet, Josep, Van Veldhuisen, Dirk J., Filippatos, Gerasimos S., Anker, Stefan D. and Ponikowski, Piotr (2022) Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency. European Journal of Heart Failure, 24 (5). pp. 821-832. doi:10.1002/ejhf.2478 ISSN 1879-0844.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: https://doi.org/10.1002/ejhf.2478
Abstract
Aim
Intravenous ferric carboxymaltose (FCM) has been shown to improve overall quality of life in iron-deficient heart failure with reduced ejection fraction (HFrEF) patients at a trial population level. This FAIR-HF and CONFIRM-HF pooled analysis explored the likelihood of individual improvement or deterioration in Kansas City Cardiomyopathy Questionnaire (KCCQ) domains with FCM versus placebo and evaluated the stability of this response over time.
Methods and results
Changes versus baseline in KCCQ overall summary score (OSS), clinical summary score (CSS) and total symptom score (TSS) were assessed at weeks 12 and 24 in FCM and placebo groups. Mean between-group differences were estimated and individual responder analyses and analyses of response stability were performed. Overall, 760 (FCM, n = 454) patients were studied. At week 12, the mean improvement in KCCQ OSS was 10.6 points with FCM versus 4.8 points with placebo (least-square mean difference [95% confidence interval, CI] 4.36 [2.14; 6.59] points). A higher proportion of patients on FCM versus placebo experienced a KCCQ OSS improvement of ≥5 (58.3% vs. 43.5%; odds ratio [95% CI] 1.81 [1.30; 2.51]), ≥10 (42.4% vs. 29.3%; 1.73 [1.23; 2.43]) or ≥15 (32.1% vs. 22.6%; 1.46 [1.02; 2.11]) points. Differences were similar at week 24 and for CSS and TSS domains. Of FCM patients with a ≥5-, ≥10- or ≥15-point improvement in KCCQ OSS at week 12, >75% sustained this improvement at week 24.
Conclusion
Treatment of iron-deficient HFrEF patients with intravenous FCM conveyed clinically relevant improvements in health status at an individual-patient level; benefits were sustained over time in most patients.
Item Type: | Journal Article | ||||||||
---|---|---|---|---|---|---|---|---|---|
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School | ||||||||
SWORD Depositor: | Library Publications Router | ||||||||
Journal or Publication Title: | European Journal of Heart Failure | ||||||||
Publisher: | Wiley | ||||||||
ISSN: | 1879-0844 | ||||||||
Official Date: | May 2022 | ||||||||
Dates: |
|
||||||||
Volume: | 24 | ||||||||
Number: | 5 | ||||||||
Page Range: | pp. 821-832 | ||||||||
DOI: | 10.1002/ejhf.2478 | ||||||||
Status: | Peer Reviewed | ||||||||
Publication Status: | Published | ||||||||
Re-use Statement: | ** Article version: VoR ** From Crossref journal articles via Jisc Publications Router ** History: epub 13-03-2022; issued 13-03-2022. ** Licence for VoR version of this article starting on 13-03-2022: http://onlinelibrary.wiley.com/termsAndConditions#vor | ||||||||
Access rights to Published version: | Open Access (Creative Commons) | ||||||||
Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |